EUVIMEDEUVIMED entdecken
Crossref

Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation

Swati Singh, Supriya Bhardwaj, Iman Dandapath, Jyotsna Singh, Sumanta Das, Trishala Mohan, Santanu Kumar Bora, Shweta Kedia, Ashish Suri, Mehar Chand Sharma, Chitra Sarkar, Mohammed Faruq und 1 weitere

Pathology - Research and Practice · 2024

DOI: 10.1016/j.prp.2024.155571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Swati Singh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neuropathology Laboratory, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy for CNS tumors is in its nascent phase, hindered by the low levels of circulating tumor DNA (ctDNA). Overcoming this challenge requires highly sensitive molecular techniques. DD-PCR emerges as a standout technique due to its ability to identify rare mutations, copy number variations, and circulating nucleic acids, making it one of the best methods for identifying somatic mutations in cell-free DNA (cfDNA). Despite promising results from various studies demonstrating the feasibility of obtaining informative ctDNA profiles from liquid biopsy samples, challenges persist, including the need to standardize sample collection, storage, and processing methods, define clear assay positivity thresholds, and address the overall low assay sensitivity. Our two-phase study began by assessing DD-PCR efficacy in FFPE tissues, revealing robust concordance with immunohistochemistry. In Phase 1 (85 cases), DD-PCR on FFPE tissues demonstrated 100 % sensitivity and specificity for IDH1 R132H mutations. In Phase 2 (100 cases), analysis extended to cfDNA, maintaining high specificity (100 %) with moderate sensitivity (44.2 %). Overall concordance with immunohistochemistry was 61 %, highlighting liquid biopsy's potential in glioma management. The findings emphasized DD-PCR's clinical utility in both tissue and liquid biopsy, underscoring its role in early detection, diagnosis, and therapeutic monitoring of diffuse gliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseGliomaMutationBrain NeoplasmsBiomarkers, TumorHumansMaleMiddle AgedFemaleAdultAgedLiquid BiopsyCirculating Tumor DNACell-Free Nucleic AcidsSensitivity and SpecificityYoung Adult

Stichwörter der Autor:innen

Cell free DNAClinical utilityDigital Droplet PCRIsocitrate Dehydrogenase 1Non-invasive

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanBiomarkers, TumorCirculating Tumor DNACell-Free Nucleic Acids

Autor:innen und Institutionen

  • Neuropathology Laboratory, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
  • CSIR Institute of Genomics and Integrative Biology, Delhi, India.
  • Neuropathology Laboratory, All India Institute of Medical Sciences, New Delhi, India. Electronic address: surivaishali@yahoo.co.in.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Singh, S., Bhardwaj, S., Dandapath, I., Singh, J., Das, S., Mohan, T., Bora, S. K., Kedia, S., Suri, A., Sharma, M. C., Sarkar, C., Faruq, M., & Suri, V. (2024). Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155571

Vancouver

Singh S, Bhardwaj S, Dandapath I, Singh J, Das S, Mohan T, et al. Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155571

BibTeX
@article{Singh2024,
  author = {Singh, Swati and Bhardwaj, Supriya and Dandapath, Iman and Singh, Jyotsna and Das, Sumanta and Mohan, Trishala and Bora, Santanu Kumar and Kedia, Shweta and Suri, Ashish and Sharma, Mehar Chand and Sarkar, Chitra and Faruq, Mohammed and Suri, Vaishali},
  title = {Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation},
  journal = {Pathology - Research and Practice},
  year = {2024},
  doi = {10.1016/j.prp.2024.155571}
}
Kostenlos starten →